Lab
Laboratorio Neoclinico INC.
Laboratorio Neoclinico INC. was paid $366K by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 18% of everything it billed.
33Billing provider infoLABORATORIO NEOCLINICO INC.
TOA BAJA, PR 00949
TOA BAJA, PR 00949
33aNPI1609247881assigned 10/13/2015
33bProvider typeClinical Medical Laboratory
28Total paid$366K
24GClaims23,935
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#331 of 777
Median peer was paid$278K
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,012 | $48K | |
| 2019 | 1,256 | $9K | |
| 2020 | 3,440 | $70K | |
| 2021 | 3,397 | $88K | |
| 2022 | 2,997 | $71K | |
| 2023 | 2,840 | $35K | |
| 2024incomplete | 3,993 | $44K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 18% | 1,686 | 1,466 | $67K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 18% | 2,812 | 2,411 | $65K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 16% | 1,232 | 1,105 | $60K |
| 84443 | Thyroid stimulating hormone (TSH) | 9.1% | 2,114 | 1,945 | $33K |
| 80061 | Lipid panel | 6.3% | 1,811 | 1,655 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.2% | 3,052 | 2,759 | $23K |
| 80053 | Comprehensive metabolic panel | 6.0% | 2,208 | 2,016 | $22K |
| 86328 | 3.6% | 753 | 658 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.6% | 1,047 | 936 | $10K |
| 36415 | Collection of venous blood by venipuncture | 2.2% | 1,203 | 1,066 | $8K |
| 81000 | 1.7% | 2,015 | 1,845 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 197 | 194 | $6K |
29 more codes
| 84436 | 1.1% | 627 | $4K | |
| 82274 | 1.0% | 307 | $4K | |
| 86738 | 1.0% | 272 | $4K | |
| 84479 | <1% | 624 | $4K | |
| 82043 | <1% | 558 | $3K | |
| 87276 | <1% | 101 | $1K | |
| 82570 | <1% | 264 | $1K | |
| 84439 | <1% | 135 | $1K | |
| 87275 | <1% | 101 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 80 | $925.08 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 34 | $860.48 |
| 84478 | <1% | 132 | $734.55 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26 | $657.36 |
| 80074 | <1% | 16 | $642.37 | |
| 82607 | <1% | 39 | $598.52 | |
| 82465 | <1% | 133 | $560.73 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 19 | $497.20 |
| 87088 | <1% | 54 | $460.30 | |
| 86592 | <1% | 94 | $360.33 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 41 | $340.57 |
| 86696 | <1% | 17 | $276.20 | |
| 86701 | <1% | 25 | $241.45 | |
| 86695 | <1% | 17 | $192.30 | |
| 86694 | <1% | 14 | $174.76 | |
| 86038 | <1% | 14 | $171.34 | |
| 86703 | <1% | 15 | $160.30 | |
| 86430 | <1% | 15 | $82.63 | |
| 86140 | <1% | 15 | $78.96 | |
| 85651 | <1% | 16 | $55.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPANTOJA, DARLING (PRESIDENT)